Instylla’s Embrace® Hydrogel Embolic System Receives FDA Approval for Peripheral Arterial Bleeds

First and Only Liquid Embolic Approved for Both Peripheral Arterial Bleeds and Hypervascular Tumors Supported by Two Prospective, Multicenter Pivotal Clinical Trials BURLINGTON, Mass., October 29th, 2026 – Instylla, Inc., a privately held company advancing resorbable embolics for peripheral vascular embolization, announced today that the U.S. Food and Drug Administration (FDA) has approved the expanded […]